Phaseline

Targets › CLN7

CLN7 (Major facilitator superfamily domain-containing protein 8): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Feb 2028.

Outward-rectifying chloride channel involved in endolysosomal chloride homeostasis, membrane fusion and function. Conducts chloride currents up to hundreds of picoamperes. (UniProt, Q8NHS3)

Open in Phaseline: the race on CLN7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Benjamin GreenbergAAV9/CLN7
AAV9-mediated gene therapy delivering CLN7
CLN7Phase 1CLN7Feb 2028

Conditions

CLN7 (1)

Modalities

other (1)

Companies

Benjamin Greenberg (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.